{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:41:04Z","timestamp":1792528864263,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jchromb.2026.125060","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:20:07Z","timestamp":1775316007000},"page":"125060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and validation of a reverse-phase HPLC method for quantification of gemcitabine in plasma samples of solid tumor patients"],"prefix":"10.1016","volume":"1277","author":[{"given":"Khushboo","family":"Bisht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusrat","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritika","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamgain","family":"Mukesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshi","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Dhamija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra S.","family":"Handu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jchromb.2026.125060_bb0005","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/ajhp\/54.2.162","article-title":"Gemcitabine: a cytidine analogue active against solid tumors","volume":"54","author":"Hui","year":"1997","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"Suppl. 6","key":"10.1016\/j.jchromb.2026.125060_bb0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00001813-199512006-00005","article-title":"Safety profile of gemcitabine","volume":"6","author":"Tonato","year":"1995","journal-title":"Anti-Cancer Drugs"},{"issue":"14","key":"10.1016\/j.jchromb.2026.125060_bb0015","first-page":"4417","article-title":"Evaluation of the antitumor activity of gemcitabine (2\u2032,2\u2032-difluoro-2\u2032-deoxycytidine)","volume":"50","author":"Hertel","year":"1990","journal-title":"Cancer Res."},{"issue":"4 Suppl 11","key":"10.1016\/j.jchromb.2026.125060_bb0020","first-page":"3","article-title":"Gemcitabine: metabolism, mechanisms of action, and self-potentiation","volume":"22","author":"Plunkett","year":"1995","journal-title":"Semin. Oncol."},{"issue":"22","key":"10.1016\/j.jchromb.2026.125060_bb0025","first-page":"6110","article-title":"Action of 2\u2032,2\u2032-difluorodeoxycytidine on DNA synthesis","volume":"51","author":"Huang","year":"1991","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.jchromb.2026.125060_bb0030","first-page":"521","article-title":"Synergistic interaction between cisplatin and gemcitabine in vitro","volume":"2","author":"Bergman","year":"1996","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.jchromb.2026.125060_bb0035","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/0006-2952(93)90444-2","article-title":"Kinetic studies on 2\u2032,2\u2032-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase","volume":"45","author":"Bouffard","year":"1993","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.jchromb.2026.125060_bb0040","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","article-title":"A phase i clinical, plasma, and cellular pharmacology study of gemcitabine","volume":"9","author":"Abbruzzese","year":"1991","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jchromb.2026.125060_bb0045","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/BF00685109","article-title":"Saturation of 2\u2032,2\u2032-difluorodeoxycytidine 5\u2032-triphosphate accumulation by mononuclear cells during a phase i trial of gemcitabine","volume":"27","author":"Grunewald","year":"1991","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.jchromb.2026.125060_bb0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1200\/JCO.1997.15.1.310","article-title":"Maximum-tolerated dose defined for single-agent gemcitabine: a phase i dose-escalation study","volume":"15","author":"Fossella","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jchromb.2026.125060_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-016-3003-0","article-title":"Pharmacokinetics and pharmacogenetics of gemcitabine as a cornerstone in adult and pediatric oncology: an EORTC-PAMM perspective","volume":"78","author":"Ciccolini","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"5","key":"10.1016\/j.jchromb.2026.125060_bb0060","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.farmac.2004.01.013","article-title":"Comparison of zero- and second-order derivative spectrophotometric and HPLC methods for the determination of gemcitabine in human plasma","volume":"59","author":"Yilmaz","year":"2004","journal-title":"Il Farmaco."},{"issue":"12","key":"10.1016\/j.jchromb.2026.125060_bb0065","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jssc.200600534","article-title":"Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC","volume":"30","author":"Lanz","year":"2007","journal-title":"J. Sep. Sci."},{"issue":"9","key":"10.1016\/j.jchromb.2026.125060_bb0070","first-page":"59","article-title":"Development and validation of a rapid and simple reversed-phase HPLC method for the determination of gemcitabine in human plasma","volume":"6","author":"Vidal","year":"2014","journal-title":"Int J Pharm Pharm Sci"},{"key":"10.1016\/j.jchromb.2026.125060_bb0075","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/862592","article-title":"Stability-indicating HPLC determination of gemcitabine in pharmaceutical formulations","volume":"2015","author":"Singh","year":"2015","journal-title":"Int J Anal Chem."},{"key":"10.1016\/j.jchromb.2026.125060_bb0080","doi-asserted-by":"crossref","first-page":"089","DOI":"10.7324\/JAPS.2024.189998","article-title":"Central composite design aided optimization and validation of developed an eco-friendly HPLC method for the quantification of lenalidomide loaded mesoporous silica nanoparticles","volume":"15","author":"Gupta","year":"2024","journal-title":"J Appl Pharm Sci"},{"issue":"1","key":"10.1016\/j.jchromb.2026.125060_bb0085","article-title":"Quality by design based ecofriendly HPLC analytical method for simultaneous quantification of erastin and lenalidomide in mesoporous silica nanoparticles","volume":"15","author":"Gupta","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jchromb.2026.125060_bb0090","doi-asserted-by":"crossref","DOI":"10.1080\/20565623.2024.2355038","article-title":"A comprehensive approach for detection of biotin deficiency from dried blood spot samples using liquid chromatography-mass spectrometry","volume":"10","author":"Raveendran","year":"2024","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.jchromb.2026.125060_bb0095","series-title":"Validation of Analytical Procedures: Text and Methodology Q2(R1)","author":"ICH Harmonised Tripartite Guideline","year":"2005"},{"key":"10.1016\/j.jchromb.2026.125060_bb0100","series-title":"International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)","year":"2023"},{"key":"10.1016\/j.jchromb.2026.125060_bb0105","first-page":"1584","article-title":"Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector","volume":"12","author":"Neng-ming","year":"2004","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jchromb.2026.125060_bb0110","first-page":"60","article-title":"Development and validation of a simple and reliable HPLC-UV method for determining gemcitabine levels: application in pharmacokinetic analysis","volume":"60","author":"Lafazanis","year":"2024","journal-title":"Medicina 2024"},{"key":"10.1016\/j.jchromb.2026.125060_bb0115","series-title":"PKanalix Version R2023","author":"Lixsoft","year":"2023"},{"key":"10.1016\/j.jchromb.2026.125060_bb0120","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jmsacl.2024.10.001","article-title":"Liquid chromatography-mass spectrometric method for the simultaneous analysis of branched-chain amino acids and their ketoacids from dried blood spot as secondary analytes for the detection of maple syrup urine disease","volume":"34","author":"Raveendran","year":"2024","journal-title":"J. Mass Spectrom. Adv. Clin. Lab"},{"issue":"5","key":"10.1016\/j.jchromb.2026.125060_bb0125","first-page":"279","article-title":"A phase i study of bi-weekly gemcitabine and docetaxel as front-line treatment in patients with advanced solid tumours","volume":"10","author":"Saif","year":"2008","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"10.1016\/j.jchromb.2026.125060_bb0130","first-page":"65","article-title":"An improved HPLC method for therapeutic drug monitoring of gemcitabine in patients with advanced solid tumours","volume":"21","author":"Fogli","year":"1999","journal-title":"Ther. Drug Monit."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226001492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023226001492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:33:52Z","timestamp":1792528432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023226001492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":26,"alternative-id":["S1570023226001492"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.125060","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a reverse-phase HPLC method for quantification of gemcitabine in plasma samples of solid tumor patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2026.125060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125060"}}